Recent

% | $
Quotes you view appear here for quick access.

Response Genetics, Inc Message Board

batterupbymandm 186 posts  |  Last Activity: 14 hours ago Member since: Jul 2, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Lets talk near and mid term catalyst

    by batterupbymandm Apr 19, 2015 11:47 AM
    batterupbymandm batterupbymandm 14 hours ago Flag

    June 22nd is only 8 days ahead of the second half of the year so I would call it that as well. What will move this stock is the announcement that EPI Pen has been approved with an AB rating. I don't think the exact date of initial manufacture will be so much of a catalyst compared to the approval.

    Sentiment: Strong Buy

  • Reply to

    Lets talk near and mid term catalyst

    by batterupbymandm Apr 19, 2015 11:47 AM
    batterupbymandm batterupbymandm 19 hours ago Flag

    Yes, from what I have read, Teva expects to launch on the settlement date of June 22nd 2015. I have not seen anything different than that. I do expect the FDA will announce the highly expected AB rating ahead of that date and I am all in anticipating that as well as Sumatriptan news which I expect within the next two weeks. Hopefully they live up to my expectations :)

    Sentiment: Strong Buy

  • Reply to

    Lets talk near and mid term catalyst

    by batterupbymandm Apr 19, 2015 11:47 AM
    batterupbymandm batterupbymandm 21 hours ago Flag

    Thanks Andre, the only figure that sticks out to me as odd is the fact that you have suma at .49 of Pt and EPI at .50 ? I would think EPI will contribute at least 1.00 if not more but maybe I misinterpreted the projections ?? Thanks

    Sentiment: Strong Buy

  • Reply to

    Lets talk near and mid term catalyst

    by batterupbymandm Apr 19, 2015 11:47 AM
    batterupbymandm batterupbymandm 22 hours ago Flag

    Do you realize ACAD went from $2 to $30 something with no approved products,,, we have about 5 or 6 and counting. We could rocket

    Sentiment: Strong Buy

  • Reply to

    Lets talk near and mid term catalyst

    by batterupbymandm Apr 19, 2015 11:47 AM
    batterupbymandm batterupbymandm 23 hours ago Flag

    Nam, Yes they discussed the milestone during the February 2015 Investor presentation. I wrote in my notes- Undisclosed Milestone upon Launch of Sumatriptan and net profit 50/50. The big question will be how much is the milestone and what kind of revenue can we reasonable expect from sumatriptan.

    Sentiment: Strong Buy

  • batterupbymandm batterupbymandm Apr 19, 2015 6:35 PM Flag

    While I agree that all eyes are on an AB rated EPI and it will in itself be a major game changer, there are many irons in the fire at Antares beyond this one product. In addition to Otrexup we have Zomacton w/Ferring, Elestrin w/Meda, Glenique w/Actavis. We have 4 pending products with Teva (including EPI), an OTC gel w/Pfizer and a pending Life Cycle Management drug with an undisclosed partner. There are dozens of other drug combinations that have been identified that could use Antares Technology in the future. Again, I agree that all eyes are on EPI but this company has a lot going for it now and looks better than ever. It amazes me that we are trading at 2.77 and I expect that to change very soon.

    Sentiment: Strong Buy

  • Reply to

    Panic Selling

    by hju1900 Apr 19, 2015 6:24 AM
    batterupbymandm batterupbymandm Apr 19, 2015 5:58 PM Flag

    Personally I think Teva will acquire Antares Pharma (ATRS) due to the fact that Teva will be using Antares injectors in four products including the EPI Pen which is likely to receive an AB rating. Teva will be spending a lot of money for injectors and it will certainly be cheaper for them to own the company. The merger would also benefit future drug endeavors. Time will tell.

    Sentiment: Strong Buy

  • batterupbymandm batterupbymandm Apr 19, 2015 5:37 PM Flag

    What kind of price are you expecting from Sumatriptan (Should be within next 2 weeks)

    Sentiment: Strong Buy

  • batterupbymandm by batterupbymandm Apr 19, 2015 11:47 AM Flag

    I was thinking today about near term catalyst and the following came to mind. I was hoping others may have ideas as well so please add to the discussion. Thanks.
    1) Sumatriptan news should be within the next two weeks. (undisclosed milestone at launch, plus 50/50)
    2) EPI Pen with Potential AB rating between now and June 22nd 2015
    3) Earnings 2nd week in May with new revenue from EPI Pens shipped in Q1
    4) Quick shot phase 3 (release info in 2nd Quarter)
    5) Undisclosed LCM alliance product (discussed during Feb 2015 Investor conference)
    6) Otrexup sales and revenue growth slowly progressing
    7) 3 more compounds with approvals in the near future possible.
    8) Pen 2 (Exantatide) described as nice product in nice market
    9) Pen 1 undisclosed

    Sentiment: Strong Buy

  • Reply to

    takeover

    by dlr77sp Apr 18, 2015 10:25 AM
    batterupbymandm batterupbymandm Apr 18, 2015 6:53 PM Flag

    According to Mylan, its all rumor and the combination would be without sound industrial logic or cultural fit. I am watching for Teva to acquire Antares Pharma (ATRS) as Teva has four products that will be using Antares injectors for their products. The largest of the four may be the EPI Pen which has the potential of an AB rating providing a near term catalyst (Between now and June 22, 2015)

    Sentiment: Strong Buy

  • batterupbymandm batterupbymandm Apr 18, 2015 6:46 PM Flag

    You are absolutely correct and clearly Teva will not be buying Mylan. Mylan listed several reasons including the fact that they are committed to a stand alone strategy and fully plan to continue their intended purchase of Perrigo. Mylan indicated they have studied the thought of being purchased by Teva and found the combination was without sound industrial logic or cultural fit. I see that Perrigo shares fell $9 dollars interday when the rumor came out but recovered as Mylan gave their clarity on the rumor. Perrigo shares recovered and in fact were up 1.52 after the close. ATRS could see a nice pop at the open on Monday.

    Sentiment: Strong Buy

  • Reply to

    TEVA / MYLAN AND MISC THOUGHTS

    by tappyt_2014 Apr 18, 2015 11:55 AM
    batterupbymandm batterupbymandm Apr 18, 2015 3:32 PM Flag

    I have listened to Mylans response to the rumor and its pretty clear that they are committed to a stand alone policy and if Teva is buying another company, its not Mylan

    Sentiment: Strong Buy

  • Reply to

    Market Manipulation is Treachery!

    by nyweatherguy Apr 17, 2015 3:33 PM
    batterupbymandm batterupbymandm Apr 18, 2015 9:32 AM Flag

    Antares management has stated repeatedly that their relationship with Teva is better than ever. I am very optimistic about ATRS and I'm very pleased that they are partnered with Teva on several products. Antares management has also said that if Teva gets an AB rating on the EPI Pen it will CHANGE THE FACE OF ANTARES. To me that is a very powerful statement and a good sign of what's ahead. I do not have any concerns but I will feel way better once the EPI gets approval and an AB rating.

    Sentiment: Strong Buy

  • Reply to

    SCRIPTS

    by bindroy Apr 17, 2015 8:31 AM
    batterupbymandm batterupbymandm Apr 18, 2015 8:14 AM Flag

    Revenue continues to grow and apparently changes made to sales force and insurance changes ARE WORKING ! This is an excellent sign. I'm pleased that Antares management took steps to keep this product launch progressing.

    Sentiment: Strong Buy

  • Reply to

    Market Manipulation is Treachery!

    by nyweatherguy Apr 17, 2015 3:33 PM
    batterupbymandm batterupbymandm Apr 18, 2015 4:53 AM Flag

    I have no idea what the price would be. To make an accurate estimate we would have to know how much Antares will receive for each injector and the potential market for the products . Considering there are four pending products, the largest that we know of is EPI Pen. There is also Sumatriptan, Pen 1 and Pen 2. We do know that if EPI is AB rated it will involve the sale of millions of Injectors to Teva. I am not here for a buyout but I am a long term investor in the company. I think that if a buyout were to happen, it would likely occur after the approval of one of more of the products above.

    Sentiment: Strong Buy

  • Reply to

    Market Manipulation is Treachery!

    by nyweatherguy Apr 17, 2015 3:33 PM
    batterupbymandm batterupbymandm Apr 17, 2015 8:01 PM Flag

    Very true, smart money is just creating an opportunity to scoop up some cheaper shares before ATRS makes the sudden move higher, which could certainly come at anytime now. The whole Teva/Mylan thing is a farce and I don't see that deal ever happening. What is likely is that Teva would buy Antares after successful product launches on one or more of the four pending products they have together. It will be cheaper for Teva to own Antares than it will be for them to buy millions of injectors from them. You also make a good point about the timing of the Zacks report and todays Teva/Mylan rumor...

    Sentiment: Strong Buy

  • batterupbymandm batterupbymandm Apr 17, 2015 7:31 PM Flag

    whogo, you sold all your ATRS stock today. Some of us have considerable investment here and we believe that Antares and Teva will execute their plan as they have stated. Please don't come on here with rumor simply to give yourself the opportunity to buy back in lower.

    Sentiment: Strong Buy

  • Reply to

    Not a word from ATRS

    by samyarabian Apr 17, 2015 3:59 PM
    batterupbymandm batterupbymandm Apr 17, 2015 4:07 PM Flag

    There is nothing to say. Stocks don't go straight up. We have had a very nice run lately and as a result the RSI was over 70. When that happens, there is typically a pullback. There was a lot of volume today, particularly in the last half hour as many grabbed cheap shares. I added today as well. There is nothing to worry about, this is normal stock activity with a little bit of manipulation/short covering.

    Sentiment: Strong Buy

  • batterupbymandm by batterupbymandm Apr 16, 2015 10:22 AM Flag

    That may be holding some buyers off until it drops a little. Many investors will not add or buy when RSI is that high.

    Sentiment: Strong Buy

  • batterupbymandm batterupbymandm Apr 16, 2015 10:17 AM Flag

    The good news is a non event but the bad news was certainly a bad event for longs when it hit. Im glad its over and it certainly removed a cloud of uncertainty that may have prevented some investors from buying or adding until it was resolved.

    Sentiment: Strong Buy

RGDX
0.31-0.03(-8.53%)Apr 20 4:00 PMEDT